Patents Assigned to New England Medical Center Hospital
-
Patent number: 6240925Abstract: A method of selectively enhancing the effect of photothermal vascular targeting on tumor regression by administration of a bioreductive agent is disclosed.Type: GrantFiled: March 23, 1999Date of Patent: June 5, 2001Assignees: Cynosure, Inc., New England Medical Center Hospitals, Inc.Inventors: Kathleen McMillan, Frederic M. Durville
-
Patent number: 6214968Abstract: A method for identifying individuals with a propensity for pathological fibrosis. The method involves providing a sample from an individual with a chronic inflammatory disease, contacting the sample with an antibody specific for fibroblast stimulating factor-1 (FsF-1) under conditions which permit immunocomplex formation, and detecting an increase in the relative level of the immunocomplex as an indication of a propensity for pathological fibrosis. FsF-1 polypeptides and antibodies specific for FsF-1, and DNA sequences encoding FsF-1 polypeptides are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: April 10, 2001Assignee: New England Medical Center Hospitals, Inc.Inventors: David J. Wyler, Sadhana Prakash, Xiaoping Zhang
-
Patent number: 6153387Abstract: Disclosed is substantially pure NES1 polypeptide and purified DNA, vectors, and cells encoding that polypeptide. Also disclosed are methods for carcinoma detection and treatment using the NES1 sequence.Type: GrantFiled: November 30, 1998Date of Patent: November 28, 2000Assignee: New England Medical Center Hospitals, Inc.Inventor: Vimla Band
-
Patent number: 6067466Abstract: A method for evaluating a medical condition of a patient including the steps of monitoring one or more clinical features of a patient; based on the monitored features, computing a primary probability of a medical outcome or diagnosis; computing a plurality of conditional probabilities for a selected diagnostic test, the computed conditional probabilities including a first probability of the medical outcome or diagnosis assuming the selected diagnostic test produces a first outcome and a second probability of the medical outcome or diagnosis assuming the selected diagnostic test produces a second outcome; and displaying the computed primary probability as well as the plurality of computed conditional probabilities to a user as an aid to determining whether to administer the selected diagnostic test to the patient.Type: GrantFiled: November 18, 1998Date of Patent: May 23, 2000Assignee: New England Medical Center Hospitals, Inc.Inventors: Harry P. Selker, John L. Griffith, Joni R. Beshansky
-
Patent number: 6026816Abstract: A method for treating sleep-disordered breathing syndromes, for example, snoring in a mammal. The method involves applying energy, for example, energy from laser light, to a preselected region of soft palate tissue in the mammal in an amount and duration sufficient to induce thermal injury to subepithelial tissue in the preselected region of soft palate tissue while minimizing thermal injury to epithelial tissue in the preselected region of soft palate tissue. Thermal injury of the subepithelial tissue results in stiffening of the preselected region of soft palate tissue thereby ameliorating the symptoms of the sleep-disordered breathing syndrome.Type: GrantFiled: January 22, 1998Date of Patent: February 22, 2000Assignees: Candela Corporation, New England Medical Center Hospitals, Inc.Inventors: Kathleen McMillan, James C. Hsia, Stanley M. Shapshay, Anthony J. Durkin
-
Patent number: 6015787Abstract: The invention features fusion proteins that contain a calpastatin peptide and a signal sequence capable of delivering the fusion protein into a cell, and uses thereof.Type: GrantFiled: November 4, 1997Date of Patent: January 18, 2000Assignee: New England Medical Center Hospitals, Inc.Inventors: David A. Potter, Paul R. Skolnik
-
Patent number: 5998380Abstract: A method for treating migraine in non-epileptic subjects which involves administering to subjects an effective amount of a pharmaceutical composition comprising a sulfamate of the following formula: ##STR1##Type: GrantFiled: October 13, 1995Date of Patent: December 7, 1999Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce L. Ehrenberg, Anita K. Wagner
-
Patent number: 5998578Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells. The subject invention further concerns antibodies that are immunoreactive with human IL-1.beta. proteins.Type: GrantFiled: June 7, 1995Date of Patent: December 7, 1999Assignees: New England Medical Center Hospitals, Inc., Massachusetts Institute of Technology, Trustees of Tufts College, Wellesley CollegeInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff, deceased
-
Patent number: 5989804Abstract: E6-BP polypeptides, nucleic acids encoding E6-BP polypeptides, and uses thereof.Type: GrantFiled: November 14, 1995Date of Patent: November 23, 1999Assignee: New England Medical Center Hospitals, Inc.Inventors: Elliot J. Androphy, Jason J. Chen
-
Patent number: 5985657Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: June 7, 1995Date of Patent: November 16, 1999Assignees: New England Medical Center Hospitals, Tufts College, Wellesley College, Massachusetts Institute of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5972348Abstract: The application discloses a nickel binding protein and its encoding DNA isolated from Helicobacter pylori. This organism is the primary cause of chronic gastritis and ensuing peptic ulcers, and has been implicated in stomach cancer. The nickel binding protein is useful to inhibit assembly of active ureases, the enzymes responsible for the pathogenic features of the bacterium. Potential uses include as a vaccine, a diagnostic, a drug target, and a therapy in itself.Type: GrantFiled: July 14, 1998Date of Patent: October 26, 1999Assignee: New England Medical Center Hospitals Inc.Inventors: Andrew G. Plaut, Joanne V. Gilbert-Rothstein, Andrew Wright
-
Patent number: 5955293Abstract: The present invention relates to a substantially pure antigenic peptide or protein related to Shiga toxin, Shiga-like toxin I, Shiga-like toxin II or a variant of Shiga-like toxin II, and to a vaccine formulation containing such a peptide or protein useful in treating a disease associated with the toxin. Also disclosed is a method for treating a disorder associated with the expression of Shiga toxin or a Shiga-like toxin using an effective amounts of the P1 glycoprotein. Antibodies may be generated to Shiga-like toxin II of the present invention that cross-react with Shiga toxin and Shiga-like toxin I. Also disclosed are methods for removing Shiga toxin or a Shiga-like toxin from a sample such as a body fluid using the antibody or the P1 glycoprotein. Also provided are methods and kits for detecting disorders associated with the expression of Shiga toxins and Shiga-like toxins I and II involving the detection of the toxins.Type: GrantFiled: May 16, 1994Date of Patent: September 21, 1999Assignee: New England Medical Center Hospitals, Inc.Inventors: Gerald T. Keusch, Arthur Donohue-Rolfe, David W. K. Acheson
-
Patent number: 5843694Abstract: The expression and purification of normal epithelial specific polypeptide (NES 1) which is expressed in normal cells, but not in radiation transformed cells, are described. Both the DNA sequence encoding the NES1 and the corresponding amino acid sequence are disclosed. Also, disclosed are methods for carcinoma detection and treatment using the NES1 as well as methods of identifying compounds modulating the expression and activity of NES1.Type: GrantFiled: April 5, 1996Date of Patent: December 1, 1998Assignee: New England Medical Center Hospitals, Inc.Inventor: Vimla Band
-
Patent number: 5830679Abstract: Disclosed is a method of diagnosing sepsis in a human infant. The method includes detecting an increase in the expression of leukocyte cell surface antigens in a blood sample from an infant at risk for developing sepsis.Type: GrantFiled: February 27, 1997Date of Patent: November 3, 1998Assignee: New England Medical Center Hospitals, Inc.Inventors: Diana W. Bianchi, Nancy Weinschenk
-
Patent number: 5821051Abstract: An assay for screening test compounds to indentify agents which modulate the binding of an E6-BP polypeptide with a papilloma virus E6 protein. The assay includes combining, as a cell-free system, an E6-binding protein or fragment thereof which binds to the E6 protein, and a test compound, and detecting the formation of a complex which includes the E6 protein and the E6-binding protein. A change in the formation of the complex in the presence of the test compound is indicative of an agent that modulates interaction between an E6 and an E6-binding protein.Type: GrantFiled: April 29, 1997Date of Patent: October 13, 1998Assignee: New England Medical Center HospitalsInventors: Elliot Androphy, Jason J. Chen
-
Patent number: 5807745Abstract: The present invention relates to a method of inhibiting (reducing or preventing) the interaction of a cell which bears a surface molecule that interacts with a ligand comprising a Le.sup.x core with its target ligand by contacting the cell with an inhibitor comprising a Lewis x (Le.sup.x) core. The invention further relates to a method of inhibiting (reducing or preventing) the interaction or adhesion of endothelial cells and/or platelets with leukocytes (i.e., white blood cells), especially with nonlymphocytic leukocytes such as neutrophils and monocytes, by contacting the endothelial cells and/or platelets with an inhibitor comprising a Le.sup.x core under conditions whereby adhesion is inhibited.Type: GrantFiled: January 26, 1995Date of Patent: September 15, 1998Assignee: New England Medical Center Hospitals, Inc.Inventors: Bruce Furie, Barbara C. Furie, Eric Larsen, Theresa Palabrica, Susan A. Sajer, Denisa D. Wagner
-
Patent number: 5800821Abstract: A method of stimulating a vertebrate animal to produce an immune response to at least one antigen is described. The method includes genetically engineering a bacterial cell with DNA encoding at least one antigen and inducing the bacterial cell to sporulate, then orally administering the bacterial spores to an animal. The bacterial spores germinate in the gastrointestinal tract of the animal and express the antigen so that it comes into contact with the animal's immune system and elicits an immune response.Type: GrantFiled: March 10, 1995Date of Patent: September 1, 1998Assignees: New England Medical Center Hospitals, Inc., Trustees of Tufts CollegeInventors: David W. K. Acheson, Abraham L. Sonenshein, Gerald T. Keusch
-
Patent number: 5792833Abstract: E2-BP polypeptides, nucleic acids encoding E2-BP polypeptides, and uses thereof.Type: GrantFiled: December 22, 1994Date of Patent: August 11, 1998Assignee: New England Medical Center Hospitals, Inc.Inventors: Elliot J. Androphy, David E. Breiding
-
Patent number: 5780040Abstract: The application discloses a nickel binding protein and its encoding DNA isolated from Helicobacter pylori. This organism is the primary cause of chronic gastritis and ensuing peptic ulcers, and has been implicated in stomach cancer. The nickel binding protein is useful to inhibit assembly of active ureases, the enzymes responsible for the pathogenic features of the bacterium. Potential uses include as a vaccine, a diagnostic, a drug target, and a therapy in itself.Type: GrantFiled: June 8, 1994Date of Patent: July 14, 1998Assignees: Tufts University School of Medicine Hospital, Inc., New England Medical Center Hospital, Inc.Inventors: Andrew G. Plaut, Joanne V. Gilbert-Rothstein, Andrew Wright
-
Patent number: 5770384Abstract: E2-BP polypeptides, nucleic acids encoding E2-BP polypeptides, and uses thereof.Type: GrantFiled: March 6, 1996Date of Patent: June 23, 1998Assignee: New England Medical Center Hospitals, IncInventors: Elliot J. Androphy, David E. Breiding